Stockscreener 앱 받기
5.565
0.57%
0.055
시간 외 거래:
5.57
0.005
+0.09%
전일 마감가:
$5.51
열려 있는:
$5.5
하루 거래량:
540.38K
Relative Volume:
0.37
시가총액:
$155.01M
수익:
$675.00K
순이익/손실:
$-39.95M
주가수익비율:
-2.7062
EPS:
-2.0564
순현금흐름:
$-28.67M
1주 성능:
+10.38%
1개월 성능:
+3.00%
6개월 성능:
-10.91%
1년 성능:
+17.90%
1일 변동 폭
$5.405
$5.61
1주일 범위
$4.975
$5.65
52주 변동 폭
$3.71
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
5.565 | 153.48M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | Guggenheim | Buy |
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Noble Financial Has Positive Forecast for UNCY Q3 Earnings - MarketBeat
Research Analysts Set Expectations for UNCY Q3 Earnings - MarketBeat
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
Unicycive Therapeutics (NASDAQ:UNCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Nantahala Capital (UNCY) discloses 2.81M-share, 9.99% holding in Unicycive - Stock Titan
Unicycive Therapeutics (UNCY): Vivo Opportunity reports 9.99% beneficial ownership stake - Stock Titan
Noble Financial Has Pessimistic View of UNCY Q2 Earnings - MarketBeat
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Benzinga
B. Riley Adjusts Price Target on Unicycive Therapeutics to $20 From $22, Maintains Buy Rating - marketscreener.com
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Unicycive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.5, Implies 550% Upside - TradingView
Unicycive Therapeutics (NASDAQ:UNCY) Announces Quarterly Earnings Results - MarketBeat
Unicycive Therapeutics, Inc. Stock 12‑Month Price Target Cut to $32.7, Implies 554% Upside - TradingView
Unicycive Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Unicycive Therapeutics Q2 Results: EPS beats estimates by 82% - scanx.trade
Form 8K Unicycive Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Unicycive Reports Q2 2026 Results: $1.7M Net Loss, $61.4M Cash and Runway Into 2027 - TradingView
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Unicycive Reports Q2 Loss As FDA Assigns OLC Facility Inspection - Moomoo
Unicycive Therapeutics shares rise after second-quarter loss beats forecasts - Yahoo Finance
Unicycive Therapeutics stock rises 2% on second quarter earnings beat By Investing.com - Investing.com South Africa
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Unicycive Therapeutics Reports FDA Facility Inspection Assigned for OLC Manufacturing Vendor, Plans NDA Resubmission After Successful Inspection - Quiver Quantitative
Unicycive Reports $61.4M in Cash and Securities as FDA Assigns Inspection - Stock Titan
Unicycive Therapeutics (UNCY) posts $14.5M H1 loss, raises $34M equity - Stock Titan
Unicycive Therapeutics, Inc. Q2 2026: Net income $(1.72M), EPS $(0.06) — 10-Q Summary - TradingView
Unicycive Therapeutics (UNCY) Earnings Date and Reports 2026 - MarketBeat
Unicycive: Solving Launch Data Challenges with Unlimited Access to Patient Data - Veeva
Unicycive Therapeutics Inc (UNCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Unicycive Therapeutics Inc (UNCY) Stock News Today - TradingKey
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeut - natlawreview.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - MarketBeat
BlackRock, Inc. Expands Stake in Unicycive Therapeutics Inc (UNC - GuruFocus
BlackRock (UNCY holder) reports 5.3% Unicycive Therapeutics stake in Schedule 13G - Stock Titan
Unicycive Therapeutics (UNCY) director granted 47,941 RSUs with staged vesting - Stock Titan
Unicycive Therapeutics Inc (UNCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Unicycive Therapeutics Inc (UNCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Unicycive Therapeutics Inc (UNCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Unicycive Therapeutics, Inc. Revenue Breakdown – NASDAQ:UNCY - TradingView
Unicycive Therapeutics Inc (UNCY) Balance Sheet - TradingKey
Unicycive Therapeutics Inc (UNCY) Cash Flow - TradingKey
UNCY|Unicycive Therapeutics Inc|Price:5.185|Chg%:-0.215 - TradingKey
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive The - The National Law Review
Unicycive Therapeutics Inc (UNCY) Income Statement - TradingKey
Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bronstein, Gewirtz & Grossman, LLC (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics Inc (UNCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Unicycive Therapeutics Inc (UNCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.67%
0.04%
자본화:
|
볼륨(24시간):